309 related articles for article (PubMed ID: 28390289)
1. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction.
Sueta D; Suyama K; Sueta A; Tabata N; Yamashita T; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Yamamoto E; Izumiya Y; Kaikita K; Yamamoto Y; Hokimoto S; Iwase H; Tsujita K
Atherosclerosis; 2017 May; 260():116-120. PubMed ID: 28390289
[TBL] [Abstract][Full Text] [Related]
2. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.
Otani Y; Kasai H; Tanigawara Y
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):188-198. PubMed ID: 33471960
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
5. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
Koyama N; Saito K; Nishioka Y; Yusa W; Yamamoto N; Yamada Y; Nokihara H; Koizumi F; Nishio K; Tamura T
BMC Cancer; 2014 Jul; 14():530. PubMed ID: 25047123
[TBL] [Abstract][Full Text] [Related]
9. Model-based treatment optimization of a novel VEGFR inhibitor.
Keizer RJ; Gupta A; Shumaker R; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2012 Aug; 74(2):315-26. PubMed ID: 22295876
[TBL] [Abstract][Full Text] [Related]
10. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib: A Review in Refractory Thyroid Cancer.
Frampton JE
Target Oncol; 2016 Feb; 11(1):115-22. PubMed ID: 26867945
[TBL] [Abstract][Full Text] [Related]
12. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
13. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
[TBL] [Abstract][Full Text] [Related]
14. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
[TBL] [Abstract][Full Text] [Related]
16. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Majid O; Hayato S; Sreerama Reddy SH; Lalovic B; Hihara T; Hoshi T; Funahashi Y; Aluri J; Takenaka O; Yasuda S; Hussein Z
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):954-969. PubMed ID: 38528813
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer.
Fogli S; Gianfilippo G; Cucchiara F; Del Re M; Valerio L; Elisei R; Danesi R
Crit Rev Oncol Hematol; 2021 Jul; 163():103366. PubMed ID: 34051303
[TBL] [Abstract][Full Text] [Related]
19. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
20. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
